210 results
8-K
EX-1.1
LCTX
Lineage Cell Therapeutics Inc
22 Mar 24
Entry into a Material Definitive Agreement
4:15pm
laws or public policy considerations in respect thereof.
(q)No Litigation. Except as set forth in the Registration Statement or the Prospectus … such claim, litigation, arbitration, action, suit, investigation or proceeding; (E) has not received notice that any Governmental Authority has taken
8-K
EX-99.1
LCTX
Lineage Cell Therapeutics Inc
7 Mar 24
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:10pm
in lower litigation and legal expenses, as well as an overall reduction in costs incurred for services provided by third parties, consulting costs
424B5
51agis2p mpj
6 Feb 24
Prospectus supplement for primary offering
9:25am
8-K
EX-10.1
jfg6z jnt5p
6 Feb 24
Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
9:20am
8-K
EX-99.1
syp91ypj4s8n qua
10 Aug 23
LINEAGE CELL THERAPEUTICS REPORTs SECOND QUARTER 2023 FINANCIAL
4:10pm
8-K
EX-99.1
4wsntywy
11 May 23
LINEAGE CELL THERAPEUTICS REPORTs FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
4:10pm
8-K
EX-99.1
e5ssmcy
10 Nov 22
LINEAGE CELL THERAPEUTICS REPORTs THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
4:11pm
8-K
EX-10.1
gridnae dtg
7 Jul 22
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.2
jtq rlurd8y1uid
17 Jun 22
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
EX-10.1
5jp8cpr mujn5
17 Jun 22
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
EX-99.1
o9c nuj56v7uhkoq2
12 May 22
LINEAGE CELL THERAPEUTICS REPORTs FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
4:10pm